Daewoong Pharmaceutical Co., Ltd (KRX: 069620)

Daewoong Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	87,679	111,506	102,951	75,907	72,299	32,094
Short-Term Investments	4,000	3,000	10,000	97,827	104,821	97,737
Trading Asset Securities	18,635	23,179	27,700	-	-	-
Cash & Short-Term Investments	110,314	137,685	140,651	173,734	177,120	129,831
Cash Growth	-26.76%	-2.11%	-19.04%	-1.91%	36.42%	-1.92%
Accounts Receivable	165,477	137,506	142,165	121,591	118,355	167,917
Other Receivables	48,817	40,386	36,979	36,916	29,222	37,819
Receivables	214,294	177,892	179,144	159,508	147,578	205,736
Inventory	246,462	241,545	208,736	170,559	173,971	177,609
Prepaid Expenses	-	8,534	7,598	6,604	8,214	5,143
Other Current Assets	18,543	9,168	12,840	9,996	21,469	7,937
Total Current Assets	589,613	574,824	548,968	520,401	528,351	526,256
Property, Plant & Equipment	591,579	521,919	440,890	395,866	393,690	391,708
Long-Term Investments	215,482	203,792	146,335	118,369	144,876	32,834
Goodwill	-	60,848	60,848	60,848	60,848	60,848
Other Intangible Assets	318,445	80,001	84,620	81,406	73,106	78,008
Long-Term Accounts Receivable	-	-	-	569.7	522.85	-
Long-Term Deferred Tax Assets	66,443	71,304	64,136	58,565	32,572	26,657
Long-Term Deferred Charges	-	156,636	120,540	82,915	44,788	25,830
Other Long-Term Assets	92,157	97,660	93,745	91,747	87,153	102,527
Total Assets	1,877,356	1,770,311	1,563,341	1,410,687	1,366,908	1,245,668
Accounts Payable	82,257	101,099	83,401	70,852	78,785	76,703
Accrued Expenses	21,188	24,085	20,635	15,485	14,986	13,737
Short-Term Debt	84,506	167,426	141,742	56,109	57,053	9,415
Current Portion of Long-Term Debt	204,994	204,943	91,931	199,878	89,926	89,921
Current Portion of Leases	1,894	1,961	1,183	987.32	984.16	993.72
Current Income Taxes Payable	25,524	14,497	4,906	4,734	2,660	1,910
Current Unearned Revenue	58.38	59.22	30.67	-	-	1,158
Other Current Liabilities	168,054	153,047	129,004	112,615	82,356	68,242
Total Current Liabilities	588,474	667,117	472,831	460,660	326,750	262,080
Long-Term Debt	259,255	65,000	204,840	181,713	291,165	289,196
Long-Term Leases	1,326	1,941	7,015	7,008	6,562	3,404
Long-Term Deferred Tax Liabilities	4,092	5,009	4,053	3,580	4,146	2,944
Other Long-Term Liabilities	89,395	118,963	133,378	59,811	43,035	52,124
Total Liabilities	942,542	858,030	822,118	712,772	671,659	609,748
Common Stock	28,966	28,966	28,966	28,966	28,966	28,966
Additional Paid-In Capital	149,212	149,175	121,582	123,649	101,097	96,705
Retained Earnings	621,246	618,864	504,294	467,361	452,802	445,415
Treasury Stock	-2,850	-2,850	-18,360	-18,360	-29,236	-44,916
Comprehensive Income & Other	-23,937	-26,852	-28,466	-32,085	-2,635	-6,857
Total Common Equity	772,637	767,303	608,017	569,531	550,994	519,315
Minority Interest	133,761	144,978	133,206	128,384	144,255	116,606
Shareholders' Equity	934,814	912,281	741,223	697,915	695,249	635,920
Total Liabilities & Equity	1,877,356	1,770,311	1,563,341	1,410,687	1,366,908	1,245,668
Total Debt	551,974	441,270	446,711	445,695	445,690	392,930
Net Cash (Debt)	-441,660	-303,585	-306,060	-271,961	-268,570	-263,099
Net Cash Per Share	-38383.67	-26573.47	-27649.69	-24713.54	-25188.32	-25491.97
Filing Date Shares Outstanding	11.51	11.51	11.07	11.07	10.76	10.32
Total Common Shares Outstanding	11.51	11.51	11.07	11.07	10.76	10.32
Working Capital	1,139	-92,293	76,137	59,742	201,601	264,176
Book Value Per Share	67149.24	66685.66	54928.72	51451.87	51194.76	50316.93
Tangible Book Value	454,192	626,454	462,550	427,278	417,039	380,458
Tangible Book Value Per Share	39473.45	54444.60	41787.05	38600.56	38748.60	36863.02
Land	-	97,598	94,459	69,482	66,814	66,785
Buildings	-	267,669	261,085	247,556	244,998	241,226
Machinery	-	340,864	325,145	307,618	304,899	300,780
Construction In Progress	-	131,731	58,328	47,216	32,046	18,503

Source: S&P Capital IQ. Standard template. Financial Sources.